Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide ...

Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced positive topline results from its Phase 3 Casppian clinical trial evaluating the efficacy and safety of FP-001 42 mg (leuprolide ...

Advanced Gold Exploration Provides Ontario Drilling Update at Buck Lake

Advanced Gold Exploration (CSE: AUEX) (FSE: HZ2) (OTC Pink: AUHIF) ("Advanced Gold" or the "Company") is pleased to provide an update on the current drill program on its 100% owned Buck Lake property ...